20 Result(s)

Article

Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression

Allogeneic mesenchymal stromal cells (MSCs) are a safe treatment option for many disorders of the immune system. However, clinical trials using MSCs have shown inconsistent therapeutic efficacy, mostly owing t...

Olivia Sirpilla, R. Leo Sakemura, Mehrdad Hefazi… in Nature Biomedical Engineering (2024)

Article

Who wins the combat, CAR or TCR?

Chimeric antigen receptor T (CAR-T) cell therapy has drawn increasing attention over the last few decades given its remarkable effectiveness and breakthroughs in treating B cell hematological malignancies. Eve...

Kun Yun, Elizabeth L. Siegler, Saad S. Kenderian in Leukemia (2023)

Article

CAR-T Cell Therapy: the Efficacy and Toxicity Balance

Chimeric antigen receptor (CAR) T cell therapy is an immunotherapy that has resulted in tremendous progress in the treatment of patients with B cell malignancies. However, the remarkable efficacy of therapy is...

Karan L. Chohan, Elizabeth L. Siegler… in Current Hematologic Malignancy Reports (2023)

Article

GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity

Inhibitory myeloid cells and their cytokines play critical roles in limiting chimeric antigen receptor T (CART) cell therapy by contributing to the development of toxicities and resistance following infusion. ...

Michelle J. Cox, Claudia Manriquez Roman, Erin E. Tapper, Elizabeth L. Siegler… in Leukemia (2022)

Chapter

Combination Therapeutics with CAR-T Cell Therapy

Adoptive cellular immunotherapy, specifically chimeric antigen receptor T-cell (CAR-T) therapy, has recently emerged as a breakthrough treatment for multiple hematological malignancies with potential for long ...

Mohamad M. Adada, Elizabeth L. Siegler… in Gene and Cellular Immunotherapy for Cancer (2022)

Article

CRISPR Takes the Front Seat in CART-Cell Development

Chimeric antigen receptor T (CART)-cell immunotherapies have opened a door in the development of specialized gene therapies for hematological and solid cancers. Impressive response rates in pivotal trials led ...

Claudia Manriquez-Roman, Elizabeth L. Siegler, Saad S. Kenderian in BioDrugs (2021)

Article

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes

Ibrutinib therapy is associated with an increased risk of atrial fibrillation (AF) in chronic lymphocytic leukemia (CLL). Risk assessment tools and outcomes of AF in these patients are not well described.

William J. Archibald, Kari G. Rabe, Brian F. Kabat, Joerg Herrmann… in Annals of Hematology (2021)

Article

Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a ‘graft versus host’-like syndrome and poor outcomes

Theodora Anagnostou, Reona Sakemura, Cynthia L. Forsman… in Bone Marrow Transplantation (2020)

Article

CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview

The goal of this review is to firstly address the concept of chimeric antigen receptor T-cell (CAR T-cell) therapy and where it fits in the evolving landscape of the management of patients with refractory/rela...

Mohamad Mohty, Remy Dulery, Jordan Gauthier, Florent Malard… in Bone Marrow Transplantation (2020)

Article

Human chimeric antigen receptor macrophages for cancer immunotherapy

Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic malignancies, but its application to solid tumors has been challenging^1–4. Given the unique effector functions of macrophages and th...

Michael Klichinsky, Marco Ruella, Olga Shestova, Xueqing Maggie Lu… in Nature Biotechnology (2020)

Article

CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies

The advent of the genome editing era brings forth the promise of adoptive cell transfer using engineered chimeric antigen receptor (CAR) T cells for targeted cancer therapy. CAR T cell immunotherapy is probabl...

Jonathan P. Mochel, Stephen C. Ekker, Chad M. Johannes… in The AAPS Journal (2019)

Article

Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf

Autologous, patient-specific chimeric antigen receptor T-cell (CART) therapy has emerged as a powerful and potentially curative therapy for cancer, especially for CD19-positive hematological malignancies. Inde...

Marco Ruella, Saad S. Kenderian in BioDrugs (2017)